Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone800-489-4774
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions
What is Endonovo Therapeutics' stock symbol?
Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."
When is Endonovo Therapeutics' next earnings date?
Has Endonovo Therapeutics been receiving favorable news coverage?
Media coverage about ENDV stock has been trending positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Endonovo Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Endonovo Therapeutics' key competitors?
Some companies that are related to Endonovo Therapeutics include Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMCAF), Selecta Biosciences (SELB), BIOLINERX LTD/S (BLRX), PLx Pharma (PLXP), Achaogen (AKAO), Celsion (CLSN), OncoSec Medical (ONCS), Novus Therapeutics (NVUS), Helix Biopharma (HBPCF), MOTIF BIO PLC/S (MTFB), Moleculin Biotech (MBRX), Relmada Therapeutics (RLMD), Diamedica Therapeuti (DMAC) and Aptevo Therapeutics (APVO).
Who are Endonovo Therapeutics' key executives?
Endonovo Therapeutics' management team includes the folowing people:
- Mr. Alan Brian Collier, Chairman, CEO, Interim CFO & Sec. (Age 53)
- Mr. Michael Scott Mann, Pres (Age 62)
- Mr. Donald Calabria, Chief Operating Officer
- Mr. Steven Barnes, Sr. VP of Investor Relations
- Bruce Garfield, Vice-Pres of Sales & Marketing
How do I buy shares of Endonovo Therapeutics?
Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endonovo Therapeutics' stock price today?
One share of ENDV stock can currently be purchased for approximately $0.0234.
How big of a company is Endonovo Therapeutics?
Endonovo Therapeutics has a market capitalization of $11.45 million.
What is Endonovo Therapeutics' official website?
How can I contact Endonovo Therapeutics?
Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at 800-489-4774 or via email at [email protected]
MarketBeat Community Rating for Endonovo Therapeutics (OTCMKTS ENDV)
MarketBeat's community ratings are surveys of what our community members think about Endonovo Therapeutics and other stocks. Vote "Outperform" if you believe ENDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
